Becton, Dickinson and Company (BDX) Sees Large Growth in Short Interest

Becton, Dickinson and Company (NYSE:BDX) was the recipient of a large growth in short interest in April. As of April 28th, there was short interest totalling 5,461,064 shares, a growth of 91.1% from the April 13th total of 2,857,841 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 2,502,418 shares, the short-interest ratio is presently 2.2 days.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the transaction, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Garde Capital Inc. bought a new position in Becton, Dickinson and Company during the third quarter valued at $690,000. Stratos Wealth Partners LTD. raised its position in Becton, Dickinson and Company by 7.0% in the third quarter. Stratos Wealth Partners LTD. now owns 4,988 shares of the medical instruments supplier’s stock valued at $897,000 after buying an additional 326 shares in the last quarter. Mutual of America Capital Management LLC raised its position in Becton, Dickinson and Company by 20.0% in the third quarter. Mutual of America Capital Management LLC now owns 35,071 shares of the medical instruments supplier’s stock valued at $6,303,000 after buying an additional 5,850 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp raised its position in Becton, Dickinson and Company by 9.0% in the third quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 49,371 shares of the medical instruments supplier’s stock valued at $8,873,000 after buying an additional 4,058 shares in the last quarter. Finally, Northeast Investment Management raised its position in Becton, Dickinson and Company by 64.0% in the third quarter. Northeast Investment Management now owns 11,769 shares of the medical instruments supplier’s stock valued at $2,115,000 after buying an additional 4,593 shares in the last quarter. Institutional investors and hedge funds own 75.41% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) traded up 0.69% during midday trading on Tuesday, reaching $194.81. The company had a trading volume of 802,114 shares. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $195.57. The stock has a market capitalization of $41.55 billion, a price-to-earnings ratio of 32.36 and a beta of 1.04. The firm’s 50 day moving average price is $187.51 and its 200-day moving average price is $179.76.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.23 by $0.07. Becton, Dickinson and Company had a net margin of 10.67% and a return on equity of 25.37%. The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.92 billion. During the same quarter in the previous year, the business earned $2.18 earnings per share. The firm’s revenue was down 3.2% compared to the same quarter last year. Equities research analysts expect that Becton, Dickinson and Company will post $9.44 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 30th. Stockholders of record on Friday, June 9th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Wednesday, June 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and Company’s dividend payout ratio is currently 48.26%.

Several equities research analysts recently weighed in on the company. Evercore ISI raised Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. Zacks Investment Research upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 target price for the company in a research note on Tuesday, April 11th. Jefferies Group LLC reiterated a “buy” rating and set a $200.00 price target on shares of Becton, Dickinson and Company in a research report on Wednesday, March 29th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $177.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $186.09.

ILLEGAL ACTIVITY NOTICE: “Becton, Dickinson and Company (BDX) Sees Large Growth in Short Interest” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/06/20/becton-dickinson-and-co-bdx-sees-large-increase-in-short-interest-updated-updated-updated-updated.html.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply